Transcriptional regulation and pharmacogenomics

Pharmacogenomics

Volumn 12, Issue 5, 2011, Pages 655-673

  Georgitsi, Marianthi ^a   Zukic, Branka ^b   Pavlovic, Sonja ^b   Patrinos, George P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

gene regulation; pharmacogenomics; SNP; transcription; transcription profiling

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BENFLUMETOL; CAFFEINE; CISPLATIN; CLOPIDOGREL; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; ESCITALOPRAM; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A9; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAPRIL; IMIPRAMINE; IRINOTECAN; LEFLUNOMIDE; MERCAPTOPURINE; NEUROLEPTIC AGENT; ORGANIC ANION TRANSPORTER 2; PHENYTOIN; PROTEIN ABCC2; PROTEIN CES1; QUININE; SEROTONIN UPTAKE INHIBITOR; THIOPURINE METHYLTRANSFERASE; THIORIDAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ADVERSE DRUG REACTION; BLEEDING; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; CORRELATION ANALYSIS; CROHN DISEASE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERANCE; GENE EXPRESSION; GENE REGULATORY NETWORK; GENE SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LUNG NON SMALL CELL CANCER; MALARIA; MENTAL DISEASE; NONHUMAN; PHARMACOGENOMICS; REVIEW; RHEUMATOID ARTHRITIS; SHORT TANDEM REPEAT; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; GENE EXPRESSION REGULATION; GENETIC VARIATION; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSCRIPTION, GENETIC;

EID: 79955704159     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.215     Document Type: Review

References (112)

1. Fraser P, Grosveld F: Locus control regions, chromatin activation and transcription. Curr. Opin. Cell Biol. 10(3), 361-365 (1998). (Pubitemid 28287048)
2. Merika M, Thanos D: Enhanceosomes. Curr. Opin. Genet. Dev. 11(2), 205-208 (2001). (Pubitemid 32209206)
3. Cecchini KR, Raja Banerjee A, Kim TH: Towards a genome-wide reconstruction of ac-regulatory networks in the human genome. Semin. Cell Dev. Biol. 20(7), 842-848 (2009).
4. Pastinen T: Genome-wide allele-specific analysis: insights into regulatory variation. Nat. Rev. Genet. 11(8), 533-538 (2010).
5. Evans WE, Relling MV: Moving towards individualized medicine with pharmacogenomics. Nature 429(6990), 464-468 (2004). (Pubitemid 38715141)
6. Sadee W, Dai Z: Pharmacogenetics/genomics and personalized medicine. Hum. Mol. Genet. 14(2), R207-R214 (2005). (Pubitemid 41631889)
7. Bosch TM: Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy. Methods Mol. Biol. 448, 63-76 (2008).
8. Weinshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32(5), 651-662 (1980). (Pubitemid 10061685)
9. Georgitsi M, Viennas M, Gkantouna V etal.: Population-specific documentation of pharmacogenomic markers and their allelic frequencies in FINDbase. Pharmacogenomics 12(1), 49-58 (2011).
10. Fessing MY, Krynetski EY, Zambetti GP etal.: Functional characterization of the human thiopurine S-methyltransferase {TPMT) gene promoter. Bur. J. Biochem. 256(3), 510-517 (1998). (Pubitemid 28440416)
11. Spire-Vayron de la Moureyre C, Debuysere H, Fazio F etal.: Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter. Pharmacogenetics 9(2), 189-198 (1999). (Pubitemid 29359001)
12. Zukic B, Radmilovic M, Stojiljkovic M etal.: Functional analysis of the role of the TPMT gene promoter VNTR polymorphism in TPMT gene transcription. Pharmacogenomics 11(4), 547-557 (2010).
13. Spire-Vayron de la Moureyre C, Debuysere H, Mastain B etal.: Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br. J. Pharmacol. 125(4), 879-887(1998). (Pubitemid 28482633)
14. Yan L, Zhang S, Eiff B etal.: Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin. Pharmacol. Ther. 68(2), 210-219 (2000). (Pubitemid 30659176)
15. Alves S, AmorimA, FerreiraF etal.: Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity Clin. Pharmacol. Ther. 70(2), 165-174 (2001). (Pubitemid 32777769)
16. TanizawaA, Fujimori A, Fujimori Y etal.: Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl Cancer Inst. 86(11), 836-842 (1994). (Pubitemid 24164661)
17. Hoskins JM, Goldberg RM, Qu P etal.: UGTlAl*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl Cancerlnst. 99(17), 1290-1295 (2007). (Pubitemid 47394168)
18. Ando Y, Saka H, Ando M et al.: Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60(24), 6921-6926 (2000). (Pubitemid 32059164)
19. Bosma PJ, Chowdhury JR, Bakker C et al.: The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333(18), 1171-1175 (1995).
20. Beutler E, Gelbart T, Demina A: Racial variability in the UDP-glucuronosyltransferase 1 (UGTlAl) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl Acad. Sa. USA 95(14), 8170-8174 (1998). (Pubitemid 28326085)
21. Carlini LE, Meropol NJ, Bever J et al.: UGT1A7and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capechabine/irinotecan. Clin. Cancer Res. 11(3), 1226-1236 (2005). (Pubitemid 40175775)
22. Innocenti F, Undevia SD, Iyer L et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22(8), 1382-1388 (2004). (Pubitemid 41103619)
23. Massacesi C, Terrazzino S, Marcucci F et al.: Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the riskof gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy Cancer 106(5), 1007-1016 (2006).
24. Cummings J, Boyd G, Ethell BT et al.: Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation. Biochem. Pharmacol. 63(4), 607-613 (2002). (Pubitemid 34457694)
25. Cummings J, Ethell BT, Jardine L et al.: Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. Cancer Res. 63(23), 8443-8450 (2003). (Pubitemid 37553155)
26. Han JY, Lim HS, Shin ES etal.: Comprehensive analysis of UGTlA polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24(15), 2237-2244 (2006).
27. Cecchin E, Innocenti F, DAndrea M etal.: Predictive role of the UGTlAl UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J. Clin. Oncol. 27(15), 2457-2465 (2009).
28. McLeod HL, Sargent DJ, Marsh S etal.: Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J. Clin. Oncol. 28(20), 3227-3233 (2010).
29. Innocenti F, Kroetz DL, Schuetz E et al.: Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J. Clin. Oncol. 27(16), 2604-2614 (2009).
30. Sugatani J, Kojima H, UedaA etal.: The phenobarbkal response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGTlAl gene and regulation by the nuclear receptor CAR. Hepatology33(5), 1232-1238 (2001). (Pubitemid 32378224)
31. Innocenti F, Grimsley C, Das S et al.: Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12 (9), 725-733 (2002). (Pubitemid 36054939)
32. Sugatani J, Yamakawa K, Yoshinari K et al.: Identification of a defect in the UGTlAl gene promoter and its association with hyperbilirubinemia. Biochem. Biophys. Res. Commun. 292(2), 492-497 (2002). (Pubitemid 34694291)
33. Marsh S, Hoskins JM: Irinotecan pharmacogenomics. Pharmacogenomics 11(7), 1003-1010 (2010).
34. Bellott R, Le Morvan V, Charasson V et al.: Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene. Cancer Chemother. Pharmacol. 61(3), 481-488(2008). (Pubitemid 350275983)
35. Geshi E, Kimura T, Yoshimura M et al.: A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity. Hypertens. Res. 28(9), 719-725 (2005). (Pubitemid 41723530)
36. Nakajima M, Yokoi T, Mizutani M etal.: Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibilky in humans. J. Biochem. 125(4), 803-808 (1999). (Pubitemid 29192503)
37. Aklillu E, Carrillo JA, Makonnen E etal.: Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol. Pharmacol. 64(3), 659-669 (2003). (Pubitemid 37048569)
38. Sachse C, Brockmoller J, Bauer S etal.: Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. 47(4), 445-449 (1999). (Pubitemid 29161279)
39. Ghotbi R, Christensen M, Roh HK etal.: Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur. J. Clin. Pharmacol. 63(6), 537-546 (2007). (Pubitemid 46684487)
40. Bohanec Grabar P, Rozman B, Tomsk: M etal.: Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur. J. Clin. Pharmacol. 64(9), 871-876 (2008).
41. Shintani M, Ieiri I, Inoue K et al.: Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies. Clin. Pharmacol. Ther. 70(2), 175-182 (2001). (Pubitemid 32777770)
42. Takahashi H, Ieiri I, Wilkinson GR etal.: 5'-flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Blood 103(8), 3055-3057 (2004). (Pubitemid 38451680)
43. Kramer MA, Rettie AE, Rieder MJ etal.: Novel CYP2C9 promoter variants and assessment of their impact on gene expression. Mol. Pharmacol. 73(6), 1751-1760 (2008). (Pubitemid 351724362)
44. Desta Z, Zhao X, Shin JG et al.: Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41(12), 913-958 (2002). (Pubitemid 35168437)
45. Drogemoller BI, Wright GE, Niehaus DJ et al.: Characterization of the genetic profile of CYP2C19 in two South African populations. Pharmacogenomics 11(8), 1095-1103 (2010).
46. Mwinyi J, Hofmann Y, Pedersen RS etal.: The transcription factor GATA-4 regulates cytochrome P4502C19 gene expression. Life Sa. 86(19-20), 699-706 (2010).
47. Sim SC, Risinger C, Dahl ML etal: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79(1), 103-113 (2006). (Pubitemid 43069582)
48. Li-Wan-Po A, Girard T, Farndon P et al.: Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17 Br. J. Clin. Pharmacol. 69(3), 222-230 (2010).
49. Rudberg I, Mohebi B, Hermann M et al.: Impact of the ultrarapid CYP2C19*17 allele on serum concentration of esckalopram in psychiatric patients. Clin. Pharmacol. Ther. 83(2), 322-327 (2008).
50. Schenk PW, van Vliet M, Mathot RA et al.: The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients. PharmacogenomicsJ. 10(3), 219-225 (2010).
51. Sibbing D, Koch W, Gebhard D et al Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121(4), 512-518 (2010).
52. Tiroch KA, Sibbing D, Koch W et al Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am. Heart J. 160(3), 506-512 (2010).
53. Ragia G, Arvanitidis KI, Tavridou A et al: Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. Pharmacogenomics 10(1), 43-49 (2009).
54. Zanger UM, Fischer J, Raimundo S et al: Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11(7), 573-585 (2001). (Pubitemid 32953583)
55. Raimundo S, Fischer J, Eichelbaum M et al: Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10(7), 577-581 (2000).
56. GaedigkA, Ndjountche L, Leeder JS et al: Limited association of the 2988g > a single nucleotide polymorphism with CYP2D641 in black subjects. Clin. Pharmacol. Ther. 77(3), 228-230; author reply 230-231 (2005).
57. Dorado P, Penas-LLedo EM, de la Rubia A et al: Relevance of CYP2DG polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients. Pharmacogenomics 10(7), 1083-1089 (2009).
58. Raimundo S, Toscano C, Klein K et al: A novel intronic mutation, 2988G>A, with high predictivky for impaired function of cytochrome P450 2D6 in white subjects. Clin. Pharmacol. Ther. 76(2), 128-138 (2004). (Pubitemid 39013403)
59. Kuehl P, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383-391 (2001). (Pubitemid 32268418)
60. SO Hashimoto H, Toide K, Kitamura R et al.: Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Bur. J. Biochem. 218(2), 585-595 (1993). (Pubitemid 24003776)
61. Amirimani B, Walker AH, Weber BL et al: RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.J. Natl Cancer Inst. 91(18), 1588-1590 (1999).
62. WestlindA, Lofberg L, Tindberg N et al: Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. Biochem. Biophys. Res. Commun. 259(1), 201-205 (1999). (Pubitemid 29264018)
63. Spurdle AB, Goodwin B, Hodgson E et al: The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 12(5), 355-366 (2002). (Pubitemid 34816415)
64. Hamzeiy H, Bombail V, Plant N et al: Transcriptional regulation of cytochrome P4503A4 gene expression: effects of inherited mutations in the 5'-flanking region. Xenobiotica 33(11), 1085-1095 (2003). (Pubitemid 37500166)
65. Pakakasama S, Mukda E, Sasanakul W et al.: Polymorphisms of drug-metabolizing enzymes and risk of childhood acute lymphoblastic leukemia. Am. J. Hematol. 79(3), 202-205 (2005). (Pubitemid 40967075)
66. Rebbeck TR, Jaffe JM, Walker AH et al.: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.J. Natl Cancer Inst. 90(16), 1225-1229 (1998). (Pubitemid 28407089)
67. Plummer SJ, Conti DV, Paris PL et al: CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol. BiomarkersPrev. 12(9), 928-932 (2003). (Pubitemid 37157963)
68. Dally H, Edler L, Jager B et al: The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics 13(10), 607-618 (2003). (Pubitemid 37311147)
69. Naoe T, Takeyama K, Yokozawa T et al.: Analysis of genetic polymorphism in NQOl, GST-MT GST-TT and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin. Cancer Res. 6(10), 4091-4095 (2000).
70. Felix CA, Walker AH, Lange BJ et al: Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl Acad. Sa. USA 95(22), 13176-13181 (1998). (Pubitemid 28509544)
71. Ferreira PE, Veiga MI, Cavaco I et al: Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, East Africa. Ther. DrugMonit. 30(1), 10-15 (2008). (Pubitemid 351161093)
72. Matsumura K, Sako T, Takahashi Y et al.: Identification of a novel polymorphic enhancer of the human CYP3A4 gene. Mol. Pharmacol. 65(2), 326-334 (2004). (Pubitemid 38134260)
73. Wang D, Guo Y, Wrighton SA et al: Intronic polymorphism in CYP3A4affects hepatic expression and response to statin drugs. Pharmacogenomics J. (2010) (Epub ahead of print).
74. Han JY, Lim HS, Yoo YK et al: Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110(1), 138-147 (2007).
75. Haenisch S, Zimmermann U, Dazert E et al.: Influence of polymorphisms of ABCBl and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J. 7(1), 56-65 (2007). (Pubitemid 46322080)
76. Fujita K, Nagashima F, Yamamoto W et al: Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). Biol. Pharm. Bull. 31(11), 2137-2142 (2008).
77. Kivisto KT, Niemi M: Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm. Res. 24(2), 239-247 (2007). (Pubitemid 46072183)
78. Maeda K, Sugiyama Y: Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab. Pharmacokinet. 23(4), 223-235 (2008).
79. Niemi M, Schaeffeler E, LangT et al: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCOIBI). Pharmacogenetics 14(7), 429-440 (2004). (Pubitemid 38971233)
80. Kameyama Y, Yamashka K, Kobayashi K et al: Functional characterization of SLC01B1 (OATP-C) variants, SLC01B1*5, SLC01B1H5 and SLCOlBl*15+ C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics 15(7), 513-522 (2005). (Pubitemid 41017600)
81. Tachibana-Iimori R, Tabara Y, Kusuhara H et al: Effect of genetic polymorphism of OATP-C (SLCOlBl) on lip id-lowering response to HMG-CoA reductase inhibitors. DrugMetab. Pharmacokinet. 19(5), 375-380 (2004).
82. Nozawa T, Minami H, Sugiura S et al.: Role of organic anion transporter OATPlBl (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. DrugMetab. Dispos. 33(3), 434-439 (2005). (Pubitemid 40279945)
83. Han JY, Lim HS, Shin ES et al.: Influence of the organic anion-transporting polypeptide 1B1 (OATPlBl) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer 59(1), 69-75 (2008).
84. Rieder MJ, Reiner AP, Gage BF et al.: Effect of VKORCl haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22), 2285-2293 (2005). (Pubitemid 40740552)
85. Yuan HY, Chen JJ, Lee MT et al.: A novel functional VKORCl promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity Hum.Mol. Genet. 14(13), 1745-1751 (2005). (Pubitemid 41430097)
86. Flockhart DA, O'Kane D, Williams MS et al.: Pharmacogenetic testing of CYP2C9 and VKORCl alleles for warfarin. Genet. Med. 10(2), 139-150 (2008). (Pubitemid 351271726)
87. Limdi NA, Beasley TM, Crowley MR et al.: VKORCl polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 9(10), 1445-1458 (2008).
88. Horie N, Chimoto M, Nozawa Ret al: Characterization of regulatory sequences and nuclear factors that function in cooperation with the promoter of the human thymidylate synthase gene. Biochim. Biophys. Acta 1216(3), 409-416 (1993). (Pubitemid 24013518)
89. Horie N, Aiba H, Oguro K et al.: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 20(3), 191-197 (1995).
90. Chu E, Koeller DM, Casey JL et al.: Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc. Natl Acad. Sci. USA 88(20), 8977-8981 (1991). (Pubitemid 21915553)
91. Kawakami K, Salonga D, ParkJM et al.: Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin. Cancer Res. 7(12), 4096-4101 (2001). (Pubitemid 34044633)
92. Mandola MV, Stoehlmacher J, Muller-Weeks S et al.: A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 63(11), 2898-2904 (2003). (Pubitemid 36667162)
93. Pullarkat ST, Stoehlmacher J, Ghaderi V et al.: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1(1), 65-70 (2001). (Pubitemid 33757985)
94. Leichman CG, Lenz HJ, Leichman L et al.: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol. 15(10), 3223-3229 (1997). (Pubitemid 27419335)
95. Lecomte T, Ferraz JM, Zinzindohoue F et al.: Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin. Cancer Res. 10(17), 5880-5888 (2004). (Pubitemid 39180969)
96. Kawakami K, Omura K, Kanehira E et al.: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res. 19(4B), 3249-3252 (1999). (Pubitemid 30042617)
97. Lenz HJ, Leichman CG, Danenberg KD et al.: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J. Clin. Oncol. 14(1), 176-182 (1996). (Pubitemid 26020011)
98. Villafranca E, OkruzhnovY, DominguezMA et al.: Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol. 19(6), 1779-1786(2001). (Pubitemid 32230880)
99. Krajinovic M, Costea I, Chiasson S: Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet359(9311), 1033-1034 (2002). (Pubitemid 34286543)
100. Weekes CD, Nallapareddy S, Rudek MA et al.: Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capeckabine for 2nd line treatment of advanced pancreatic cancer. Lnvest. New Drugs (2010) (Epubaheaf of print).
101. Marsh S, Collie-Duguid ES, Li T et al: Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 58(3), 310-312 (1999). (Pubitemid 29300314)
102. Marsh S, Ameyaw MM, Githang'aJ et al: Novel thymidylate synthase enhancer region alleles in African populations. Hum. Mutat. 16(6), 528 (2000).
103. Luo HR, Lu XM, YaoYG et al: Length polymorphism of thymidylate synthase regulatory region in Chinese populations and evolution of the novel alleles. Biochem. Genet. 40(1-2), 41-51 (2002).
104. HishidaA, Matsuo K, HamajimaN et al: Associations between polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and susceptibility to malignant lymphoma. Haematologica 88(2), 159-166 (2003). (Pubitemid 37101493)
105. Nief N, le Morvan V, Robert J: Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel. Eur. J. Cancer 43(5), 955-962 (2007). (Pubitemid 46366695)
106. Kawakami K, Watanabe G: Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res. 63(18), 6004-6007 (2003). (Pubitemid 37187503)
107. Marcuello E, Altes A, del Rio E et al: Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int. J. Cancer 112(5), 133-131 (2004).
108. Lincz LF, Scorgie FE, Garg MB et al.: Identifcation of a novel single nucleotide polymorphism in the frst tandem repeat sequence of the thymidylate synthase 2R allele. Int. J. Cancer 120(9), 1930-1934 (2007). (Pubitemid 46418369)
109. Gusella M, Bolzonella C, Crepaldi G et al.: A novel G/C single-nucleotide polymorphism in the double 28-bp repeat thymidylate synthase allele. Pharmacogenomics J. 6(6), 421-424 (2006). (Pubitemid 44811538)
110. Ulrich CM, Bigler J, Velicer CM et al.: Searching expressed sequence tag databases: discovery and confrmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol. Biomarkers Prev. 9(12), 1381-1385 (2000). (Pubitemid 32044809)
111. Lenz HJ, Zhang W, Zahedy S et al.: A 6 base-pair deletion in the 3́UTR of the thymidylate synthase (TS) gene predicts TS mRNA expression in colorectal tumors: a possible candidate gene for colorectal cancer risk. Proc. Annu. Meet. Am. Assoc. Cancer Res. 43, 3274 (2002).
112. Mandola MV, Stoehlmacher J, Zhang W et al.: A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14(5), 319-327 (2004). (Pubitemid 38638919)